AIBOLIT 3D+
AIbolit Technologies, LLC • Radiology • 01/07/2022
Device Purpose
Aibolit 3D+ is a web-based medical imaging software that transforms CT DICOM data into interactive 3D anatomical models to aid in preoperative surgical planning, training, and intraoperative visualization. The system employs a radiologist-driven workflow, incorporating features like organ segmentation, transparent viewing, and AI-assisted annotation, to provide clinicians with enhanced spatial understanding of patient anatomy.
Summary
Aibolit 3D+ is a medical imaging software system designed for the processing, review, analysis, and communication of multi-dimensional digital images acquired from CT imaging devices. Its primary purpose is to support healthcare professionals in preoperative surgical planning, training, patient education, and as an intraoperative display tool, ultimately assisting clinicians in making final patient management decisions. The system operates as a web-based, stand-alone application that processes DICOM CT images to generate interactive 3D anatomical models. These models can be manipulated for viewing from various perspectives, offering features like transparent views of structures, identification of artifacts such as ducts, vessels, lesions, and entrapped calcifications, and differential coloration for highlighting regions of interest. The scientific basis of Aibolit 3D+ involves advanced image processing to convert standard CT scans into detailed 3D visualizations that can be manipulated for viewing, including features like organ segmentation, dimensional and volume references, multi-axis image rotation, organ transparency, and organ retraction animation. The workflow initiates with a physician uploading DICOM images and specifying desired anatomical segments. A radiologist then annotates these images, with the option of using AI/ML algorithms under their control and approval. Subsequently, an imaging technician generates a multi-axis rotatable image and retraction model. After a final review by the radiologist, the enhanced images, which can include organ structure dimensions, volume, labels, patient ID, and CT date, are made available to the requesting physician. This process aims to improve the surgeon's decision-making during planning, review, and conduct of surgical procedures by enhancing the identification of anatomical structures and their positional relationships.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance (e.g., accuracy, processing time) of Aibolit 3D+'s AI-assisted annotation compare to purely manual annotation by radiologists for various anatomical regions?; What specific quantitative benefits, such as reduction in surgical planning time or improvement in anatomical landmark identification accuracy, have been observed with the use of Aibolit 3D+ compared to standard 2D CT review?; Can Aibolit 3D+ integrate with other surgical navigation or robotic systems, and what is the process for exporting models for such use?; What are the limitations of the "organ retraction animation" feature, particularly in complex cases with significant adhesions or anatomical variations?; How does the system ensure the fidelity and accuracy of the 3D models, especially concerning measurements of critical structures like vessels or tumor margins, across different CT scanner protocols?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly